p14ARF/CDKN2A Antibody [DyLight 405]

Novus Biologicals, part of Bio-Techne | Catalog # NB110-59085V

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Western Blot

Label

DyLight 405 (Excitation = 400 nm, Emission = 420 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all p14ARF/CDKN2A Antibodies »

Product Specifications

Immunogen

A synthetic peptide made to a portion of human p14ARF (between residues 100-173). [Swiss-Prot# Q8N726]

Localization

Nuclear, nucleolar

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for p14ARF/CDKN2A Antibody [DyLight 405]

Application
Recommended Usage

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: p14ARF/CDKN2A

ARF (alternative reading frame; p14ARF in human, p19ARF in mouse) is a tumor suppressor that serves as a sensor of hyper-proliferative signals, resulting in p53-dependent growth arrest and apoptotic cell death. ARF interacts with several proteins including COMMD1, CDKN2AIP, TBRG1, E4F1, C1QBP etc. and can bind to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI as well as UBE2I/UBC9. ARF has the capability of inducing cell cycle arrest in G1 as well as G2 phases. While ARF is not expressed at significant levels in most normal tissues, oncogene activation triggers ARF overexpression, resulting in inhibition of MDM2 ubiquitin ligase and stabilization of p53. It is induced by progesterone as well as Ras/DMTF1, and is downregulated through NFkB p65 subunit (RELA). Inhibition of the p53 pathway, most commonly via mutations in p53 itself, inactivation of ARF, or amplification of MDM2 has been proposed to be a crucial step in pathogenesis of most human malignancies. Moreover, mice with null ARF have been shown to develop tumors rapidly and to display delayed mammary gland involution.

Alternate Names

ARF, CDK4 inhibitor p16-INK4, CDK4IP14ARF, CDKN2, cell cycle negative regulator beta, CMM2P16-INK4A, Cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4), INK4, INK4A, MLMP16INK4, MTS-1, MTS1P14, Multiple tumor suppressor 1, p14, p14ARF, P16, p16-INK4, P16INK4A, p16-INK4a, p19, P19ARF, TP16

Gene Symbol

CDKN2A

Additional p14ARF/CDKN2A Products

Product Documents for p14ARF/CDKN2A Antibody [DyLight 405]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for p14ARF/CDKN2A Antibody [DyLight 405]



DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.